Condition
Multiple Sclerosis-Relapsing-Remitting
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06276634Not ApplicableRecruiting
Intermittent Hypoxia in Persons With Multiple Sclerosis
NCT06381297Not ApplicableCompletedPrimary
Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.
NCT02137707CompletedPrimary
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
Showing all 3 trials